跳至主要内容
临床试验/EUCTR2014-001277-14-GB
EUCTR2014-001277-14-GB进行中(未招募)1 期

A Randomised Mechanistic Study Comparing the Effects of Different Anti-platelet Combinations (Ticagrelor vs. Placebo/ Clopidogrel) with Aspirin in Patients presenting with STEMI Treated with Primary PCI - TIMES

Royal Papworth Hospital NHS Foundation Trust0 个研究点目标入组 140 人开始时间: 2015年12月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • For inclusion in the study subjects should fulfill the following criteria:
  • 1. Provision of informed verbal consent prior to any study specific procedures taking place with written consent confirmed prior to in-patient cardiac MRI.
  • 2. Male or female adult patient aged 18 – 90 years old
  • 3. Any STEMI (ST elevation = 2mm in contiguous chest leads) with chest pain symptom onset < 24 hours
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 70
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
  • 1. Cardiogenic shock
  • 2. Previous myocardial infarction in the infarct-related artery requiring intervention
  • 3. Unfavourable coronary anatomy for PCI: left main/surgical or distal coronary disease
  • 4. Already prescribed Ticagrelor at the time of admission
  • 5. Factors affecting study drug administration/ absorption: vomiting or allergy to the IMP
  • 6. Concomitant use of potent CYP3A4 inhibitors/ inducers (e.g ketoconazole and rifampicin) or CYP3A4 substrates with a narrow therapeutic window (e.g. cisapride and ergot alkaloids) or simvastatin / lovostatin >40mg oral dose.
  • 7. Severe bleeding diathesis or current active bleeding
  • 8. History of intracranial haemorrhage
  • 9. Known Moderate or Severe hepatic impairment or abnormal liver function tests (ALT >5x ULN) at baseline (if available)
  • 10. Severe asthma that has required hospital admission or significant bradycardia/ complete heart block diagnosed on ECG (contraindications to
  • adenosine).
  • 11. Severe co-morbidity with a life expectancy < 3 months.
  • 12. Women of child bearing age unless confirmed by direct questioning that they are reproductively sterile or post-menopausal.
  • 13. Concomitant treatment with anticoagulants.

研究者

相似试验